Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Giulia Siravegna et al.|The Lancet Oncology|2016Cited by 1k
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Marcello Gambacorta, Cosimo Martino et al.|Modern Pathology|2015Cited by 317
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort studyWouter Froyman, D. Timmerman, C. Landolfo et al.|The Lancet Oncology|2019Cited by 188
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomasYmera Pignochino, Francesco Leone|BMC Cancer|2010Cited by 174
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patientGiuliana Cavalloni, Francesco Leone|Tumor Biology|2015Cited by 40